Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

current therapies.  Zerenex has the potential to be an effective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

The market for phosphate binders to treat hyperphosphatemia in ESRD patients in 2009 was approximately $750 million and $1.3 billion in the U.S. and worldwide, respectively.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Calif. , March 30, 2015  The investigational ... agent to alleviate certain menopause symptoms, such as hot ... March Journal of Women,s Health .[i] ... S- equol for menopausal vasomotor symptoms and possibly ... supporting safety of S- equol, physicians and health ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... the addition of the "Urological Catheters ... to their offering. This report ... in Thousand Units and US$ Thousands by ... Catheters, & Peritoneal Catheters), and Urinary Catheters ...
(Date:3/30/2015)... 2015 Research and Markets ( ... "Marine Biotechnology - Global Strategic Business Report" ... estimates and forecasts are provided for the period ... is provided for these markets. Market data and ... This report analyzes the worldwide markets ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 2Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 3Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 4Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 5Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 7Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced completion ... has now completed the final trial necessary to support a ... an NDA in the first half of 2011.  LEVADEX is ... 3 clinical development for the acute treatment of migraine. ...
... 21, 2010 Bellicum Pharmaceuticals, Inc. today announced $3 ... be used to prepare for Phase II trials of ... prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy safety ... therapy (HSCT) setting. The new funding brings ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 On ... blue polo for yellow to inspire courage in Seth ... from Severe Combined Immunodeficiency (SCID). SCID causes affected individuals ... marrow transplant is needed to allow the development of ... transplant last Friday, created a video with his family ...
(Date:3/30/2015)... GenSight ®, provider of an ... a leader in The Forrester Wave™: Strategic Planning For ... The independent report positions GenSight as a leader and ... of 5) for the analytics, corporate strategy, assessment, direction ... GenSight’s position in the Leaders category. , According to ...
(Date:3/30/2015)... York, NY (PRWEB) March 30, 2015 V/NO ... that includes a convenient flute for opening/closing and for reuse. ... wine on the go. Health-conscious New Yorkers, professionals, and basically ... is sophisticated yet delicious to kick back socially or pair ... arise. , “ V/NO is dealcoholized wine and that ...
(Date:3/30/2015)... The “Orthopedic Software Market [By ... By Applications (Orthopedic Surgery, Joint Replacement, Fracture ... – Global Forecast to 2020” analyzes and ... in North America, Europe, Asia-Pacific and the ... before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=94720371 , This ...
Breaking Medicine News(10 mins):Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 3Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 4
... Fund and Sustain to Raise ... Donations after Floods, ... the decimation of a number of organic and family farms,in Minnesota ... farmers, nonprofits, restaurants and natural,food cooperatives to implement a multifaceted, region-wide ...
... Meeting Expectations today announced,that it has been ... of the industry,s,largest and most influential full-service independent ... corporate market. Compiled by,Penton Media,s Corporate Meetings & ... billion corporate meetings and events,industry, the CMI 25 ...
... of us have never heard of immune infertility, yet ... Immune infertility is one of 80 autoimmune disorders, a ... Type 1 Diabetes. This reproductive disorder affects both men ... on sperm. , A recent discovery at the University ...
... N.J., Sept. 12 Leaders of the,medical community ... association to address increasing concerns that the quality ... of the practice of medicine, are,in jeopardy. ... was,created to provide a strong, unified voice for ...
... Medina General Hospital and,University Hospitals announced today ... which Medina General has indicated its desire to ... network of,community- based hospitals. The agreement is subject ... regulatory and governance approvals. "We,re excited about ...
... joins Growing Company, METAIRIE, La., Sept. 12 ... orthodontic and dental practices,worldwide, has hired David Ward ... experience will be invaluable to serving our existing,doctors ... of our,company," said Chris Roussos, president and CEO ...
Cached Medicine News:Health News:Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations 2Health News:Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations 3Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2Health News:UVA researchers find important clue to immune infertility 2Health News:New Jersey Physicians Launch New, Statewide Association to Fight for Stronger Voice in Healthcare 2Health News:Medina General Hospital and University Hospitals Agree to Pursue Affiliation 2Health News:David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: